Abstract
Egeberg et al1 enriched us by describing the limitations of registries in psoriasis, but focusing their critical perspective on a misguided outcome measure such as "drug survival". We agree that clinicians and researchers should be cautious when using that proxy measure.2,3However, the frequent use of this poor outcome should not cast doubts over all the capabilities of registries.
This article is protected by copyright. All rights reserved.
http://ift.tt/2xnLR9d
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου